tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael King, 125 are a BUY (99.21%), 1 are a HOLD (0.79%).
Analyst Michael King, currently employed at RODMAN & RENSHAW, carries an average stock price target met ratio of 50.79% that have a potential upside of 51.1% achieved within 317 days. Previously, Michael King worked at BENCHMARK, JMP, HC WAINWRIGHT.
Michael King’s has documented 247 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 10-Mar-2026.
Analyst best performing recommendations are on NTLA (INTELLIA THERAPEUTICS).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS) at 6/28/2021. The price target of $171 was fulfilled within 3 days with a profit of $37.57 (28.16%) receiving and performance score of 93.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Mar-2025
$318
$69.32 (27.88%)
$380
26 days ago
(19-Aug-2026)
33/36 (91.67%)
$75.39 (31.07%)
270
Hold Since 20-Oct-2025
$256
$7.32 (2.94%)
$316
1 months ago
(14-Aug-2026)
2/6 (33.33%)
$27.35 (11.96%)
38
Buy Since 21-Jul-2025
$315
$66.32 (26.67%)
$410
1 months 10 days ago
(04-Aug-2026)
4/9 (44.44%)
$96 (43.84%)
11
Buy Since 29-Jul-2025
$420
$171.32 (68.89%)
$472
1 months 11 days ago
(03-Aug-2026)
4/5 (80%)
$199.67 (90.62%)
19
Buy Since 28-Jun-2024
$450
$201.32 (80.96%)
$527
1 months 11 days ago
(03-Aug-2026)
1/3 (33.33%)
$229.67 (104.24%)
110
What Year was the first public recommendation made by Michael King?
